Cargando…

Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.

CA 242, a novel tumour carbohydrate antigen present in serum (upper limit of normal values: 20.0 U ml-1), has been measured in a group of 102 pathologically confirmed non-small cell lung cancer patients. The aim of the present prospective study was to identify any relationship between pre-treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pujol, J. L., Cooper, E. H., Lehmann, M., Purves, D. A., Dan-Aouta, M., Midander, J., Godard, P., Michel, F. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968478/ https://www.ncbi.nlm.nih.gov/pubmed/8390291

Ejemplares similares

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.
por: Ward, U., et al.
Publicado: (1993)

Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
por: Pasanen, P. A., et al.
Publicado: (1992)

The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer.
por: Hall, N. R., et al.
Publicado: (1994)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991)

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
por: Pasanen, P. A., et al.
Publicado: (1993)

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
por: Haglund, C., et al.
Publicado: (1989)

Comparative study of CA242 and CA19-9 in chronic pancreatitis.
por: Furuya, N., et al.
Publicado: (1996)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer
por: Dong, Dong, et al.
Publicado: (2018)

Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
por: Kawa, S., et al.
Publicado: (1994)

Performance evaluation of CA242 by flow fluorescence assay
por: Hou, Yanyan, et al.
Publicado: (2021)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

Intralobar pulmonary sequestration with aspergillus infection and elevated serum CA19-9 and CA242: a case report
por: Ge, Li, et al.
Publicado: (2021)

Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer
por: Luo, Hai, et al.
Publicado: (2020)

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
por: Haglund, C., et al.
Publicado: (1986)

Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1996)

Correlation of Serum CA242, CA724, and TPA Levels with Clinicopathological Features and Prognosis in Patients with Inflammatory Bowel Disease Complicated with Rectal Cancer
por: Liang, Hongliang, et al.
Publicado: (2022)

Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
por: Nilsson, O., et al.
Publicado: (1992)

A Label-Free Electrochemical Immunosensor for Detection of the Tumor Marker CA242 Based on Reduced Graphene Oxide-Gold-Palladium Nanocomposite
por: Du, Xin, et al.
Publicado: (2019)

Genetic variation at 16q24.2 is associated with small vessel stroke
por: Traylor, Matthew, et al.
Publicado: (2017)

Health Tract, No. 242: Emergencies
Publicado: (1866)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

SUN-242 Transcriptome of the Amygdala in Normal Cyclic and Acyclic Gilts
por: Lents, Clay A, et al.
Publicado: (2020)

Selective inhibition of Toll-like receptor 4 signaling by the small molecule TAK-242
por: Kawamoto, T, et al.
Publicado: (2006)

Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection
por: Heng, Gang, et al.
Publicado: (2022)

A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
por: Pasanen, P. A., et al.
Publicado: (1994)

Frequency of serum tumour marker monitoring.
por: Colls, B. M.
Publicado: (1991)

Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours.
por: Fizazi, K., et al.
Publicado: (1997)

Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis
por: Boher, J-M, et al.
Publicado: (1999)

Serum proteins as tumour markers for breast cancer.
por: Mattison, P., et al.
Publicado: (1981)

A novel electrochemical immunosensor based on PdAgPt/MoS(2) for the ultrasensitive detection of CA 242
por: Cao, Linlin, et al.
Publicado: (2022)

Novel small molecule TRVA242 targets neuromuscular junction in amyotrophic lateral sclerosis
por: Bose, Poulomee
Publicado: (2019)

IAU Symposium 242: Astrophysical masers and their environments
Publicado: (2007)

Analysis of 242 Cases of Sprue in Indian Troops
por: Karamchandani, P. V., et al.
Publicado: (1946)

242 Characterization of Maternal Stress During Pregnancy
por: Dhaliwal, Satvinder K., et al.
Publicado: (2022)

Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
por: Seckl, M. J., et al.
Publicado: (1990)

Lung tumour markers in oncology practice: a study of TPA and CA125
por: Buccheri, G, et al.
Publicado: (2002)

Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
por: Haglund, C., et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_0kved850oqlp669c6lsno5btic